The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.

Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.

The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.

The present invention provides live-attenuated bacterium of the genus Salmonella comprising a recombinant plasmid encoding a fusion protein, wherein the fusion protein comprises a coronavirus antigen and an adjuvant peptide.

Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.

Provided herein is a multivalent Brucella vaccine expressing at least one heterologous M. tuberculosis antigen. The vaccines described herein serve as an environmentally safe bivalent vaccine for protection against Brucella and Mycobacterium infections simultaneously. In particular, a multivalent vaccine comprising a Brucella strain transformed with a vector that expresses at least one M. tuberculosis antigen, where the M. tuberculosis antigen(s) is codon optimized for the Brucella strain is provided. In some aspects, the Brucella strain is B. abortus strain RB51 leuB and the M. tuberculosis antigen is one or more of Ag85B, Rv2660c, and ESAT6.

A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.

The present invention relates to a strain of Salmonella enteritidis 3934vac, which has been deleted the waaL gene to obtain a rough phenotype (3934vac DwaaL), the obtaining procedure and the oligos used with the objective of reducing toxicity and maintaining immunogenicity for its application as a vaccine. Another aspect of the present invention relates to a strain of Salmonella enteritidis 3934vac DwaaL, i.e. rough type, which has been modified to express the gene of the avian adenovirus type I fiber, in addition to the procedure for obtaining a Salmonella enteritidis 3034 vac DwaaL strain expressing an AvA-I fiber gene. The invention also comprises the development of a new, live, recombinant, effective and innocuous avian vaccine against the AvA-I virus developed via an insertion and integration process of AvA-I fiber genes in the chromosome of an attenuated and non-pathogenic strain of the bacterium Salmonella enteritidis.

The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.